- 期刊
- OpenAccess
Bevacizumab Suppresses Choroidal Neovascularization Caused by Pathological Myopia
Bevacizumab抑制病理性近視引起之脈絡膜血管新生
摘要
目的：評估以玻璃體內注射bevacizumab治療因病理性近視造成的視網膜病變合併脈絡膜新生血管的效果。 方法：自2006年2月至2008年3月，共收集20位病患，將bevacizumab (Avastin) 1.25 mg (0.05 mL)注射入玻璃體內，若視網膜水腫或視網膜下積水無法完全消退，則每兩個月再注射一次。水腫或積水消退後即停止治療，觀察療效維持時間，直到再出現水腫或積水。 結果：注射次數1到5次不等，療程中以中心視網膜中央窩厚度來評估效果，並紀錄病患於治療及觀察期間最佳矯正視力之變化。中心視網膜中央窩厚度平均減少19 um，最佳矯正視力平均進步05 (logMAR)。治療效果約可維持38.7星期。 結論：玻璃體內注射bevacizumab能成功治療高度近視性視網膜病變合併脈絡膜新生血管，多數病患的最佳矯正視力都明顯進步。
關鍵字
無資料並列摘要
Purpose: To report the successful use of intravitreal bevacizumab (Avastin) in pathologic myopic patient with choroidal neovascularization. Method: From February 2006 to March 2008, we collected 20 pathologic myopic patient with CNV. They were injected intravitreally with bevacizumab (Avastin) 1.25 mg (0.05 mL). Injection was repeated at two months interval once the intraretinal edema or subretinal fluid was detected. Result Patient received injections ranging from 1 to 5 times. Efficacy was evaluated by reduction in central foveal thickness. BCVA was also recorded during treatment period. Average reduction in absolute central foveal thickness was 19 um. BCVA improved by a means of 0.5 (logMAR). Average SRF-free period was 38.7 weeks. Conclusion: Intravitreal Bevacizumab was injected successively in cases of pathologic myopia with CNV. BCVA was improved for most patients. Reduced or resolved angiographic leakage and reduction in macular thickness was noted in all our cases.
延伸閱讀
- 郭廣慈（2010）。Bevacizumab結膜下腔注射在眼輪部幹細胞缺損模式中對於角膜新生血管與角膜結膜化的抑制效果〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU.2010.00657
- 林念庭（2008）。抗血管內皮生長因子藥物Bevacizumab對抑制角膜新生血管之影響〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU.2008.00391
- Sheu, S. J. (2009). 以眼內注射Ranibizumab治療內因性眼內炎併發脈絡膜新生血管. The Kaohsiung Journal of Medical Sciences, 25(11), 617-621. https://www.airitilibrary.com/Article/Detail?DocID=1607551X-200911-200911030005-200911030005-617-621
- Chen, Y. H., Wu, W. C., Wang, N. K., Chen, T. L., Chao, A. N., Chen, K. J., Hwang, Y. S., Chen, Y. P., Liu, L., Kuo, J. Z. C., Chang, C. J., Chuang, L. H., & Lai, C. C. (2013). 合併光動力療法與眼內注射抗血管新生藥物治療多囊性脈絡膜病變之病患：一年之成效. 中華民國眼科醫學會雜誌, 52(1), 21-31. https://www.airitilibrary.com/Article/Detail?DocID=10213120-201304-201309060003-201309060003-21-31
- 曹友平、潘如瑜、蔡東瀚、賴旗俊、蔡瑞芳（2001）。關節炎、腦中風及眼內脈絡膜血管新生的基因治療。台灣醫學，5(1)，74-82。https://doi.org/10.6320/FJM.2001.5(1).10